Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study.
Masahiro AyanoYasutaka KimotoHiroki MitomaMitsuteru AkahoshiNobuyuki OnoYojiro ArinobuKoichi AkashiTakahiko HoriuchiHiroaki NiiroPublished in: Therapeutic advances in musculoskeletal disease (2022)
MZR is as effective as MMF in controlling SLE activity. The adverse events of MZR, whose profile differs from MMF, are comparable to or less than those of MMF. MZR may be a valuable option as an immunosuppressive agent for SLE, as well as MMF.